These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV. Liu D; Tian S; Zhang K; Xiong W; Lubaki NM; Chen Z; Han W Protein Cell; 2017 Dec; 8(12):861-877. PubMed ID: 28488245 [TBL] [Abstract][Full Text] [Related]
7. Natural Killer (NK) Cell Education Differentially Influences HIV Antibody-Dependent NK Cell Activation and Antibody-Dependent Cellular Cytotoxicity. Bernard NF; Kiani Z; Tremblay-McLean A; Kant SA; Leeks CE; Dupuy FP Front Immunol; 2017; 8():1033. PubMed ID: 28883824 [TBL] [Abstract][Full Text] [Related]
8. Harnessing Memory NK Cell to Protect Against COVID-19. Soleimanian S; Yaghobi R Front Pharmacol; 2020; 11():1309. PubMed ID: 32973527 [TBL] [Abstract][Full Text] [Related]
9. CAR-NK Cells: From Natural Basis to Design for Kill. Khawar MB; Sun H Front Immunol; 2021; 12():707542. PubMed ID: 34970253 [TBL] [Abstract][Full Text] [Related]
10. IFN-α augments natural killer-mediated antibody-dependent cellular cytotoxicity of HIV-1-infected autologous CD4+ T cells regardless of major histocompatibility complex class 1 downregulation. Tomescu C; Tebas P; Montaner LJ AIDS; 2017 Mar; 31(5):613-622. PubMed ID: 28225449 [TBL] [Abstract][Full Text] [Related]
11. Anticancer traits of chimeric antigen receptors (CARs)-Natural Killer (NK) cells as novel approaches for melanoma treatment. Bahmanyar M; Vakil MK; Al-Awsi GRL; Kouhpayeh SA; Mansoori Y; Mansoori B; Moravej A; Mazarzaei A; Ghasemian A BMC Cancer; 2022 Nov; 22(1):1220. PubMed ID: 36434591 [TBL] [Abstract][Full Text] [Related]
12. Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy. Liu B; Zou F; Lu L; Chen C; He D; Zhang X; Tang X; Liu C; Li L; Zhang H J Virol; 2016 Nov; 90(21):9712-9724. PubMed ID: 27535056 [TBL] [Abstract][Full Text] [Related]
13. Slaying the Trojan horse: natural killer cells exhibit robust anti-HIV-1 antibody-dependent activation and cytolysis against allogeneic T cells. Gooneratne SL; Richard J; Lee WS; Finzi A; Kent SJ; Parsons MS J Virol; 2015 Jan; 89(1):97-109. PubMed ID: 25320293 [TBL] [Abstract][Full Text] [Related]
14. Novel insights in CAR-NK cells beyond CAR-T cell technology; promising advantages. Ebrahimiyan H; Tamimi A; Shokoohian B; Minaei N; Memarnejadian A; Hossein-Khannazer N; Hassan M; Vosough M Int Immunopharmacol; 2022 May; 106():108587. PubMed ID: 35149294 [TBL] [Abstract][Full Text] [Related]
15. NK Cells Armed with Chimeric Antigen Receptors (CAR): Roadblocks to Successful Development. Bashiri Dezfouli A; Yazdi M; Pockley AG; Khosravi M; Kobold S; Wagner E; Multhoff G Cells; 2021 Dec; 10(12):. PubMed ID: 34943898 [TBL] [Abstract][Full Text] [Related]
16. Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy. Gong Y; Klein Wolterink RGJ; Wang J; Bos GMJ; Germeraad WTV J Hematol Oncol; 2021 May; 14(1):73. PubMed ID: 33933160 [TBL] [Abstract][Full Text] [Related]
17. TRIGGERED: could refocused cell signaling be key to natural killer cell-based HIV immunotherapeutics? Sugawara S; Manickam C; Reeves RK AIDS; 2021 Feb; 35(2):165-176. PubMed ID: 33116071 [TBL] [Abstract][Full Text] [Related]
18. [Allogeneic CAR-NK cells: A promising alternative to autologous CAR-T cells - State of the art, sources of NK cells, limits and perspectives]. Nguyen S; Lacan C; Roos-Weil D Bull Cancer; 2021 Oct; 108(10S):S81-S91. PubMed ID: 34920811 [TBL] [Abstract][Full Text] [Related]
19. NK cell-based therapeutics for lung cancer. Pockley AG; Vaupel P; Multhoff G Expert Opin Biol Ther; 2020 Jan; 20(1):23-33. PubMed ID: 31714156 [No Abstract] [Full Text] [Related]